betula verrucosa (Itulazax 12 SQ-Bet®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen

Medicine details

Medicine name betula verrucosa (Itulazax 12 SQ-Bet®)
Formulation Sublingual lyophilisate
Reference number 3859
Indication

For use in adults and children (5 years or older) for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE)

Company ALK-Abello Ltd
BNF chapter Immunological products & vaccines
Assessment type N/A
Status Excluded due to NICE appraisal
Date of issue 15/07/2025
NICE guidance

TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen